Hepatitis C with normal liver enzymes: To treat or not to treat. CON: Most patients should not be treated

American Journal of Gastroenterology

Volumn 99, Issue 6, 2004, Pages 973-975

  Reddy, K Rajender ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; LIVER ENZYME; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HEPATITIS C; HUMAN; MEDICAL DECISION MAKING; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT PLANNING; VIREMIA; VIRUS LOAD;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DECISION MAKING; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LIVER FUNCTION TESTS; MALE; REFERENCE VALUES; RIBAVIRIN; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 3142772237     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2004.40510_2.x     Document Type: Review

References (15)

1. Prati D, Taioli E, Zanella A. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-9.
2. Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C infection. N Engl J Med 1996;334:1691-6.
3. Gholson CF, Morgan K, Catinis G. Chronic hepatitis C with normal aminotransferase levels: A clinical histological study. Am J Gastroenterol 1997;92(10):1775-7.
4. Puoti C, Margrini A, Strati T. Clinical, histological, and virological features of hepatitis C virus carrier with persistently normal or abnormal alanine transaminase levels. Hepatology 1998;27(4):1169.
5. Mathurin P, Moussalli J, Cadranel JF. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998;277(3):868-72.
6. Jamal MM, Soni A, Quinn PG. Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States. Hepatology 1999;30(5):1307-11.
7. Inglesby TV, Rai R, Astemborski J. A prospective, community-based evaluation of liver enzymes in individual with hepatitis C after drug use. Hepatology 1999;29(2):590-6.
8. Persico M, Persico E, Suozzo R. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000;118(4):760-4.
9. Gordon SC, Fang JW, Silverman AL. The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C. Hepatology 2002;32(2):400-4.
10. Shiffman ML, Stewart CA, Hofmann CM. Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: Comparison hepatic histology and response to interferon therapy. J Infect Dis 2000;182(6):1595-601.
11. Martinot-Peignoux M, Boyer N, Cazals-Hatem D. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detect serum hepatitis C with RNA. Hepatology 2001;34(5):1000-5.
12. Puoti C, Castellacci R, Montagnese F. Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: The Italian prospective study of the asymptomatic C carriers (ISACC). J Hepatol 2002;37(1):117-23.
13. Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: Patients with normal aminotransferase levels. Hepatology 1997;26:133S-6S.
14. Zeuzem S, Diago M, Gane E, et al. International, multicenter, randomized, controlled study for the treatment of patients with chronic hepatitis C and persistently normal ALT levels with Peginterferon alfa-2a and ribavirin Hepatology-presented at AASLD 2003.
15. National Institute of Health Consensus Development Conference Statement: Management of Hepatitis C. Hepatology 2002;36(5):S3-20.